Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,355 | -13,205 | -11,876 | -9,805 | -3,926 |
| Depreciation Amortization | 200 | 199 | 68 | 18 | 6 |
| Other Working Capital | -41 | -2,142 | 1,610 | 542 | -256 |
| Other Operating Activity | -575 | -2,050 | -2,005 | 1,921 | 411 |
| Operating Cash Flow | $-17,771 | $-17,198 | $-12,203 | $-7,324 | $-3,765 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -374 | -51 | -417 | -28 | -21 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -100 |
| Investing Cash Flow | $-374 | $-51 | $-417 | $-28 | $-121 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 165 |
| Common Stock Issued | 22,566 | 20,854 | 12,045 | 10,059 | 9,170 |
| Other Financing Activity | -17 | 0 | 0 | 0 | -470 |
| Financing Cash Flow | $22,549 | $20,854 | $12,045 | $10,059 | $8,865 |
| Exchange Rate Effect | 34 | -4 | -5 | N/A | N/A |
| Beginning Cash Position | 10,735 | 7,134 | 7,714 | 5,007 | 28 |
| End Cash Position | 15,173 | 10,735 | 7,134 | 7,714 | 5,007 |
| Net Cash Flow | $4,438 | $3,601 | $-580 | $2,707 | $4,979 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,771 | -17,198 | -12,203 | -7,324 | -3,765 |
| Capital Expenditure | -376 | -52 | -417 | -28 | -21 |
| Free Cash Flow | -18,147 | -17,250 | -12,620 | -7,352 | -3,786 |